BlueAnorak
Well-Known Member
- Joined
- 31 Oct 2010
- Messages
- 30,198
Mostly Sinovac being used. 50% efficacious and still a large chance of death.
Mostly Sinovac being used. 50% efficacious and still a large chance of death.
As under 30s will be offered a different vaccine, it doesn’t matter, but as you’r asking don’t know about under 30 but 14 under 44 have died this week.At the moment how many people are dying of COVID in the under 30's? How many have even died in the last 3 months?
This is the perfect time to be highly selective of the vaccines we use as we learn more about them.
I think that was the South Africans and the later decision by the (wider) African Union followed the blood clot “findings”. The South Africans had no alternative close to being available IIRC, so it was strange decision to stop the AZ vaccine roll out given the potential protection from death.They did that because they didn't think the AZ vaccine was as efficacious for the SA variant- not for any other reason. They seem to have ignored the near 100% protection from death bit.
In the UK not many, in Europe, quite a lot, in Brazil lots.At the moment how many people are dying of COVID in the under 30's? How many have even died in the last 3 months?
This is the perfect time to be highly selective of the vaccines we use as we learn more about them.
Good grief! "After 1 person has died", they want to pause the whole program??? Utter, utter madness. Do they just not understand the "cost of doing nothing"????![]()
Johnson & Johnson vaccine paused over rare blood clots
Following rare blood clots, the US, South Africa and EU have suspended the jab.www.bbc.co.uk
Maybe they do, when from about 193m jabsGood grief! "After 1 person has died", they want to pause the whole program??? Utter, utter madness. Do they just not understand the "cost of doing nothing"????
I don't think the mRNA vaccines are affected.I think all RNA treatments are linked to thrombocytopenia too?
So arguably equally likely to be a problem for RNA vaccines?
Guessing last Tuesday’s low figure was down to the Easter break and not as many being reported as a result so not really a great barometer.England hospital deaths wk to wk
279 / 59 NW / 26% (25% fall wk to wk)
164 / 35 NW / 21% (41% fall wk to wk)
101 / 26 NW / 26% (378% fall wk to wk)
98 / 19 NW / 19% (3% fall wk to wk)
40 / 8 NW / 20% (61% fall wk to wk)
12 / 1 NW / 9% (70% fall wk to wk)
33 / 8 NW / 24% (175% RISE wk to wk) TODAY
Looks worse than it is I suspect! Hopefully!
The word vaccine comes from the latin vacco, meaning cow.
yesFrom the cowpox thing.
Interesting. Why exactly is the administration of an adenovirus triggering a clotting cascade...I don't think the mRNA vaccines are affected.
This is the Abstact of the paper I found. I searched for thrombocytopenia and adenovirus.
My emboldening. I haven't bothered reading it because there's stuff in the abstract such as Willebrand Factor, and P-selectin that I have never heard of but it sounds quite similar to the problems encountered with the COvid-19 vaccines.
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY| DECEMBER 5, 2006,
Volume 109, Issue 7
April 1 2007
Othman et al.
"Thrombocytopenia has been consistently reported following the administration of adenoviral gene transfer vectors. The mechanism underlying this phenomenon is currently unknown. In this study, we have assessed the influence of von Willebrand Factor (VWF) and P-selectin on the clearance of platelets following adenovirus administration. In mice, thrombocytopenia occurs between 5 and 24 hours after adenovirus delivery. The virus activates platelets and induces platelet-leukocyte aggregate formation. There is an associated increase in platelet and leukocyte-derived microparticles. Adenovirus-induced endothelial cell activation was shown by VCAM-1 expression on virus-treated, cultured endothelial cells and by the release of ultra-large molecular weight multimers of VWF within 1 to 2 hours of virus administration with an accompanying elevation of endothelial microparticles. In contrast, VWF knockout (KO) mice did not show significant thrombocytopenia after adenovirus administration. We have also shown that adenovirus interferes with adhesion of platelets to a fibronectin-coated surface and flow cytometry revealed the presence of the Coxsackie adenovirus receptor on the platelet surface. We conclude that VWF and P-selectin are critically involved in a complex platelet-leukocyte-endothelial interplay, resulting in platelet activation and accelerated platelet clearance following adenovirus administration."
Bloody awful figurePeople dying with Covid in the U.K. has passed 150k, according to the ONS.